Meridian bioscience stock.

Customizable interactive chart for Meridian Bioscience with latest real-time price quote, charts, latest news, technical analysis and opinions. ... Stock Market Overview Market Momentum Market Performance Top 100 Stocks Today's Price Surprises New Highs & Lows Economic Overview Earnings Within 7 Days Earnings & Dividends Stock Screener.Find Salaries by Job Title at Meridian Bioscience. 31 Salaries (for 13 job titles) • Updated Oct 29, 2023. How much do Meridian Bioscience employees make? Glassdoor provides our best prediction for total pay in today's job market, along with other types of pay like cash bonuses, stock bonuses, profit sharing, sales commissions, and tips.Meridian Bioscience, Inc. is a life science company. The Company is engaged in the development, manufacture, sale and distribution of diagnostic testing systems and kits, primarily for certain gastrointestinal and respiratory infectious diseases, and elevated blood lead levels; and the manufacture and distribution of bulk antigens, antibodies ...Track Meridian Bioscience Inc. (VIVO) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors

Meridian Bioscience, Inc. is a life science company. The Company is engaged in the development, manufacture, sale and distribution of diagnostic testing systems and kits, primarily for certain gastrointestinal and respiratory infectious diseases, and elevated blood lead levels; and the manufacture and distribution of bulk antigens, antibodies, immunoassay blocking reagents, specialized ... Jan 31, 2023 · Lourdes Weltzien owns over 20,000 units of Meridian Bioscience stock worth over $3,500,541 and over the last 5 years he sold VIVO stock worth over $0. In addition, he makes $675,550 as Executive Vice President - Life Science at Meridian Bioscience. Wallmine is a radically better financial terminal.

Mr. Phillips VIVO stock SEC Form 4 insiders trading. David has made over 8 trades of the Meridian Bioscience stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 7,500 units of VIVO stock worth $139,050 on 12 January 2022.. The largest trade he's ever made was buying 10,000 units of Meridian …

Zacks Premium Feature View All Zacks #1 Ranked Stocks · Meridian Bioscience Inc. (VIVO) Quote Overview » Zacks Research » Meridian Bioscience Inc. (VIVO) ...Summary of all time highs, changes and price drops for Meridian Bioscience; Historical stock prices; Current Share Price: US$33.97: 52 Week High: US$34.38: 52 …Jan 24, 2019 · Meridian Bioscience Inc. Dividend Stock News and Updates. Feb. 05, 2022 VIVO STOCK PRICE INCREASE: Meridian Bioscience Inc. on 02-05-2022 increased stock price > 10% from $21.38 to $23.98. Read more... Jul. 14, 2021 VIVO STOCK PRICE DECREASE: Meridian Bioscience Inc. on 07-14-2021 decreased stock price > 10% from $22.50 to $17.35. Oct 10, 2017 · l28988ae10vk.htm MERIDIAN BIOSCIENCE, INC. 10-K. MERIDEIAN BIOSCIENCE, INC. 10-K. Washington, D.C. 20549. FOR ANNUAL AND TRANSITION REPORTS PURSUANT TO SECTIONS 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934. FOR THE FISCAL YEAR ENDED SEPTEMBER 30, 2007.Section 1.4 Effect of the Merger.The Merger will have the effects set forth in this Agreement and the relevant provisions of the OGCL. Without limiting the generality of the foregoing and subject thereto, at the Effective Time, all the property, rights, privileges, immunities, powers, franchises and authority of the Company and Merger Sub will vest in the Surviving Company and all debts ...

Looking to buy Meridian Bioscience Stock? View today's VIVO stock price, trade commission-free, and discuss VIVO stock updates with the investor community.

Stock Price & Overview 4.57K followers VIVO is defunct since January 31, 2023. Acquired Summary All Comments Analysis Meridian Biosciences: Why I Moved On But May Go Back In Bram de Haas...

Oct 11, 2022 · Meridian Bioscience, Inc. is a life science company. The Company is engaged in the development, manufacture, sale and distribution of diagnostic testing systems and kits, primarily for certain gastrointestinal and respiratory infectious diseases, and elevated blood lead levels; and the manufacture and distribution of bulk antigens, antibodies, immunoassay blocking reagents, specialized ... Jul 8, 2022 · South Korean billionaire Cho Young-sik’s SD Biosensor and Seoul-based private equity firm SJL Partners said they are acquiring Nasdaq-listed diagnostics company Meridian Bioscience for $1.53 ... Historical price to book ratio values for Meridian Bioscience Inc. (VIVO) over the last 10 years. The current price to book ratio for Meridian Bioscience Inc. as of November 29, 2023 is . Please refer to the Stock Price Adjustment Guide</a> for more information on our historical prices.</p>CINCINNATI, Aug. 5, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the third quarter ended June 30, 2022.. Third …Jan 31, 2023 · The estimated Net Worth of John P. Kenny is at least 17.5 百万$ dollars as of 24 June 2022. Mr Kenny owns over 74,996 units of Meridian Bioscience stock worth over 11,093,515$ and over the last 5 years he sold VIVO stock worth over 4,939,280$. In addition, he makes 1,508,705$ as Pres、 CEO & Director at Meridian Bioscience.

Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) announces that effective today it will have completed the purchase of all the outstanding capital stock of the Bioline group of companies consisting of Bioline Ltd (UK), Bioline GmbH (Germany), Bioline (Aust) Pty Ltd (Australia), Bioline Reagents Ltd, and Bioline USA, Inc for $23.3 million in cash on hand.Meridian Bioscience Inc will be acquired by SD Biosensor Inc and PE firm SJL Partners LLC in an all-cash $1.53-billion deal, ... a 1.3% premium to the stock's closing price on Wednesday, ...Meridian Bioscience sets closing date for $1.53 billion deal finance.yahoo.com - December 12 at 5:59 PM: Meridian Bioscience (NASDAQ:VIVO) Stock Rating Reaffirmed by William Blair marketbeat.com - November 29 at 8:16 AM: Meridian Bioscience Non-GAAP EPS of $0.21, revenue of $65.67M seekingalpha.com - November 22 at 5:12 PMCompany profile page for Meridian Bioscience Inc including stock price, company news, press releases, executives, board members, and contact information.The share price of Meridian Bioscience Inc. (VIVO) is $33.97 (NASDAQ) as of 30-Jan-2023 16:00 EST. Meridian Bioscience Inc. (VIVO) has given a return of 48.09% in the last 3 years.

Meridian Bioscience, Inc. is a life science company. The Company is engaged in the development, manufacture, sale and distribution of diagnostic testing systems and kits, primarily for certain gastrointestinal and respiratory infectious diseases, and elevated blood lead levels; and the manufacture and distribution of bulk antigens, …

Dec 12, 2022 · Meridian’s stock soared 79% during that fiscal year. Newtown-based Meridian, founded in 1977, is Greater Cincinnati’s 16th-largest public company, according to Courier research. It reported ... Meridian Bioscience sets closing date for $1.53 billion deal finance.yahoo.com - December 12 at 5:59 PM: Meridian Bioscience (NASDAQ:VIVO) Stock Rating Reaffirmed by William Blair marketbeat.com - November 29 at 8:16 AM: Meridian Bioscience Non-GAAP EPS of $0.21, revenue of $65.67M seekingalpha.com - November 22 at 5:12 PMMr. Phillips VIVO stock SEC Form 4 insiders trading. David has made over 8 trades of the Meridian Bioscience stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 7,500 units of VIVO stock worth $139,050 on 12 January 2022.. The largest trade he's ever made was buying 10,000 units of Meridian …Jan 14, 2022 · Phillips owns over 7,500 units of Meridian Bioscience stock worth over $477,109 and over the last 20 years he sold VIVO stock worth over $0. In addition, he makes $148,167 as Independent Chairman of the Board at Meridian Bioscience. Wallmine is a radically better financial terminal. Sign up in seconds, it's free!Stock Meridian Bioscience, Inc. - Deutsche Boerse AG. Meridian Bioscience, Inc. (MR4.FRA) : Stock quote, stock chart, quotes, analysis, advice, financials and news for …Jan 31, 2023 · The estimated Net Worth of Catherine Sazdanoff is at least $365 Thousand dollars as of 29 April 2016. Ms. Sazdanoff owns over 7,700 units of Meridian Bioscience stock worth over $261,569 and over the last 8 years she sold VIVO stock worth over $0. In addition, she makes $103,333 as Independent Director at Meridian Bioscience.

Meridian Bioscience Inc. Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, rare reagents, specialty biologicals and components. Utilizing a variety of methods, their diagnostic tests provide accuracy, simplicity and speed in the early ...

Dec 19, 2022 · The estimated Net Worth of Bryan T Baldasare is at least $2.96 Million dollars as of 8 February 2021. Mr. Baldasare owns over 6,254 units of Meridian Bioscience stock worth over $1,906,668 and over the last 4 years he sold VIVO stock worth over $566,813. In addition, he makes $490,759 as Chief Financial Officer, Senior Vice …

Meridian Bioscience (NASDAQ:VIVO) is a fully-integrated developer of diagnostic systems through its diagnostics segment, ... That means Meridian is a highly valued stock right now, and the prices ...May 3, 2019 · View %COMPANY_NAME% VIVO investment & stock information. Get the latest %COMPANY_NAME% VIVO detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. ... Meridian Bioscience Inc ... The latest closing stock price for Meridian Bioscience on January 30, 2023 is 33.97. The all-time high Meridian Bioscience closing stock price was 33.97 on January 30, 2023. …Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 33.33% and 2.63%, respectively, for the quarter ended September 2022. Do the numbers hold clues …Meridian Bioscience announced July 7 it's entered into a definitive merger agreement to be acquired by a pair of South Korean-based firms, SD Biosensor and SJL Partners, in a deal valued at $1.53 ...A South Korean buyer consortium is acquiring US diagnostic test kit maker Meridian Bioscience (NASDAQ:VIVO). The offer is $34 per share in cash or a total of ~$1.53bn. The offer is $34 per share ...Jan 14, 2022 · Phillips owns over 7,500 units of Meridian Bioscience stock worth over $477,109 and over the last 20 years he sold VIVO stock worth over $0. In addition, he makes $148,167 as Independent Chairman of the Board at Meridian Bioscience. Wallmine is a radically better financial terminal. Sign up in seconds, it's free!Meridian Bioscience Inc will be acquired by SD Biosensor Inc and PE firm SJL Partners LLC in an all-cash $1.53-billion deal, ... a 1.3% premium to the stock's closing price on Wednesday, ...Meridian Bioscience, Inc. is a life science company. The Company is engaged in the development, manufacture, sale and distribution of diagnostic testing systems and kits, primarily for certain gastrointestinal and respiratory infectious diseases, and elevated blood lead levels; and the manufacture and distribution of bulk antigens, antibodies, immunoassay blocking reagents, specialized ...Jan 31, 2023 · John has made over 6 trades of the Meridian Bioscience stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of VIVO stock worth $37,950 on 25 February 2020.Meridian Bioscience Inc stock price live 33.97, this page displays NASDAQ VIVO stock exchange data. View the VIVO premarket stock price ahead of the market session or …2 Mei 2022 ... One of Cincinnati's largest public companies names new C-suite member · This Cincinnati company was most popular pick in annual stock contest.

Penny stocks may sound like an interesting investment option, but there are some things that you should consider before deciding whether this is the right investment choice for you.Dec 19, 2022 · The estimated Net Worth of Bryan T Baldasare is at least $2.96 Million dollars as of 8 February 2021. Mr. Baldasare owns over 6,254 units of Meridian Bioscience stock worth over $1,906,668 and over the last 4 years he sold VIVO stock worth over $566,813. In addition, he makes $490,759 as Chief Financial Officer, Senior Vice …About Meridian Bioscience, Inc. Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products.The estimated total pay for a Account Executive at Meridian Bioscience is $167,272 per year. ... Additional pay could include bonus, stock, commission, profit sharing or tips. The "Most Likely Range" represents values that exist within the 25th and 75th percentile of all pay data available for this role.Instagram:https://instagram. forbes top wealth management teamsfinancial advisor ratingsinvinity energy systemsinvestment strategies for beginners Meridian Bioscience is the IBD 50 Stocks To Watch pick for Wednesday as it eyes a new buy point and is forming a bullish base. It comes after VIVO stock ran as much as 456% above its 2020 lows. X ... ishares core sandp mid cap etfbest ira for crypto Under the terms of the agreement, Meridian shareholders will receive $34.00 per share in cash, which represents a premium of approximately 32% over Meridian's closing stock price on the day before ...2 août 2022 ... ... stock starting 7 June. Meridian Bioscience develops, produces, markets, and distributes a range of diagnostic products in areas that include ... pioneer bond fund Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms ...Dec 1, 2023 · Meridian Bioscience, Inc. (NASDAQ:VIVO) issued its earnings results on Friday, November, 12th. The company reported $0.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.21 by $0.03. The company had revenue of $76.20 million for the quarter, compared to analysts' expectations of $68.40 million.